Literature DB >> 14592545

Variants of cyclooxygenase-1 and their roles in medicine.

Daniel L Simmons1.   

Abstract

Acetaminophen (paracetamol) and other analgesic/antipyretic drugs such as dipyrone have been postulated to act centrally through inhibition of cyclooxygenases (COXs). COX activity in lipopolysaccharide-stimulated mammalian leukocytes, microglial cells, and platelets is inhibited by these drugs at physiological concentrations. Yet purified COX enzymes are poorly inhibited by acetaminophen, particularly under conditions of high oxidant tone and elevated substrate levels. This suggests the presence of cell-specific differences that govern COX inhibition by these drugs. COX-3, a variant of COX-1, has been found in canine brain and is inhibited by acetaminophen and dipyrone at physiological concentrations. Additionally, other new COX-1-derived proteins called PCOX have been identified that do not make prostaglandins but apparently bind heme and may have other enzymatic properties. Antibodies specific for these variants detect analogous proteins in human tissues. Expression of COX variants is postulated to be an integral part of the mechanism of action of analgesic/antipyretic drugs.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14592545     DOI: 10.1016/s0049-3848(03)00380-3

Source DB:  PubMed          Journal:  Thromb Res        ISSN: 0049-3848            Impact factor:   3.944


  10 in total

Review 1.  Recent methodologies toward the synthesis of valdecoxib: a potential 3,4-diarylisoxazolyl COX-II inhibitor.

Authors:  Sureshbabu Dadiboyena; Adel Nefzi
Journal:  Eur J Med Chem       Date:  2010-08-06       Impact factor: 6.514

Review 2.  Single compartment drug delivery.

Authors:  Michael J Cima; Heejin Lee; Karen Daniel; Laura M Tanenbaum; Aikaterini Mantzavinou; Kevin C Spencer; Qunya Ong; Jay C Sy; John Santini; Carl M Schoellhammer; Daniel Blankschtein; Robert S Langer
Journal:  J Control Release       Date:  2014-05-04       Impact factor: 9.776

Review 3.  Alternative splicing: functional diversity among voltage-gated calcium channels and behavioral consequences.

Authors:  Diane Lipscombe; Arturo Andrade; Summer E Allen
Journal:  Biochim Biophys Acta       Date:  2012-09-26

Review 4.  New Insights on COX-2 in Chronic Inflammation Driving Breast Cancer Growth and Metastasis.

Authors:  Honor J Hugo; C Saunders; R G Ramsay; E W Thompson
Journal:  J Mammary Gland Biol Neoplasia       Date:  2015-07-21       Impact factor: 2.673

Review 5.  Prostaglandin H synthase: resolved and unresolved mechanistic issues.

Authors:  Ah-Lim Tsai; Richard J Kulmacz
Journal:  Arch Biochem Biophys       Date:  2009-09-01       Impact factor: 4.013

6.  Selective COX-2 Inhibitors: A Review of Their Structure-Activity Relationships.

Authors:  Afshin Zarghi; Sara Arfaei
Journal:  Iran J Pharm Res       Date:  2011       Impact factor: 1.696

7.  Quantitative proteomic analysis of cultured skin fibroblast cells derived from patients with triglyceride deposit cardiomyovasculopathy.

Authors:  Yasuhiro Hara; Naoko Kawasaki; Ken-ichi Hirano; Yuuki Hashimoto; Jun Adachi; Shio Watanabe; Takeshi Tomonaga
Journal:  Orphanet J Rare Dis       Date:  2013-12-21       Impact factor: 4.123

Review 8.  ω-3 Fatty Acids and Cardiovascular Diseases: Effects, Mechanisms and Dietary Relevance.

Authors:  Hanne K Maehre; Ida-Johanne Jensen; Edel O Elvevoll; Karl-Erik Eilertsen
Journal:  Int J Mol Sci       Date:  2015-09-18       Impact factor: 5.923

Review 9.  The cyclooxygenases.

Authors:  N V Chandrasekharan; Daniel L Simmons
Journal:  Genome Biol       Date:  2004-08-27       Impact factor: 13.583

10.  Virtual screening for novel COX-2 inhibitors using the ZINC database.

Authors:  Kotaprolu Naga Sudha; Mohammed Shakira; Paturi Prasanthi; Nalla Sarika; Ch Narasimha Kumar; Padavala Ajay Babu
Journal:  Bioinformation       Date:  2008-05-13
  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.